Analysts highlight healthcare’s defensive appeal amid rising AI investment risks and geopolitical tensions.
Healthcare equities are emerging as a defensive play as investors grow wary of AI-driven volatility and geopolitical uncertainty. Strong fundamentals and bottom-up growth drivers underpin the sector’s resilience, contrasting with broader market anxieties.
Recent performance, such as Novartis’s robust results driven by cost management, underscores the sector’s stability. However, risks persist, including delayed clinical trial readouts for key drugs like Pelacarthen. While AI may enhance R&D efficiency, biological complexities and trial limitations cap near-term gains.
The shift reflects a broader rotation toward sectors less exposed to macroeconomic and technological disruptions.